Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate

Luigino Calzetta (Rome, Italy), Luigino Calzetta, Paola Rogliani, Ermanno Puxeddu, Josuel Ora, Francesco Facciolo, Maria Gabriella Matera, Mario Cazzola

Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Session: Airway pharmacology: drug targets and mode of action
Session type: Poster Discussion
Number: 5057
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Luigino Calzetta (Rome, Italy), Luigino Calzetta, Paola Rogliani, Ermanno Puxeddu, Josuel Ora, Francesco Facciolo, Maria Gabriella Matera, Mario Cazzola. Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate. Eur Respir J 2016; 48: Suppl. 60, 5057

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016

Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014

The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015


Interaction between aclidinium bromide and formoterol fumarate in small human airways
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Synergistic effects by combination of tiotropium with olodaterol result from cross talk between muscarinic and β2-adrenergic receptors via allosteric modulation
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016


Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012


Interaction between RPL554 and glycopyrronium bromide in small human airways
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

Slow dissociation kinetics of LAMAs contribute to the functional interactions with LABAs
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016

Combination study of tiotropium and olodaterol in human precision-cut lung slices
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013


Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Involvement of the BK channels/G proteins processes in the synergistic effects between anticholinergic agents and beta2-adrenoceptor agonists in airway smooth muscle
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013


Role of budesonide, formoterol fumarate and aclidinium bromide in the inflammaging of airway epithelial cells
Source: International Congress 2017 – Cigarette smoke and particulate matter: basic science and clinical aspects
Year: 2017

The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Translational study searching for synergy between glycopyrronium and indacaterol
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Endothelin-1-mediated contraction of mouse small airways is resistant to salbutamol, but sensitive to rosiglitazone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013

Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta2-agonists in dogs
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

A comparison of beta2-adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015